Alberto J. Montero
Alberto J. Montero
University Hospitals/Seidman Cancer Center Case Western Reserve University
Verified email at - Homepage
Cited by
Cited by
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
CM Diaz-Montero, ML Salem, MI Nishimura, E Garrett-Mayer, DJ Cole, ...
Cancer immunology, immunotherapy 58, 49-59, 2009
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
S Solito, E Falisi, CM Diaz-Montero, A Doni, L Pinton, A Rosato, ...
Blood, The Journal of the American Society of Hematology 118 (8), 2254-2265, 2011
Docetaxel for treatment of solid tumours: a systematic review of clinical data
A Montero, F Fossella, G Hortobagyi, V Valero
The lancet oncology 6 (4), 229-239, 2005
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative …
FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ...
Journal of Clinical Oncology 40 (28), 3246-3256, 2022
Molecular profiling for breast cancer: a comprehensive review
M Kittaneh, AJ Montero, S Glück
Biomarkers in cancer 5, BIC. S9455, 2013
Myeloid-derived suppressor cells in cancer patients: a clinical perspective
AJ Montero, CM Diaz-Montero, CE Kyriakopoulos, V Bronte, ...
Journal of immunotherapy 35 (2), 107-115, 2012
Cellular redox pathways as a therapeutic target in the treatment of cancer
AJ Montero, J Jassem
Drugs 71, 1385-1396, 2011
Treating breast cancer in the 21st century: emerging biological therapies
G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero
Journal of Cancer 4 (2), 117, 2013
Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications
CM Diaz-Montero, J Finke, AJ Montero
Seminars in oncology 41 (2), 174-184, 2014
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer
V Diaby, R Tawk, V Sanogo, H Xiao, AJ Montero
Breast câncer research and treatment 151, 27-40, 2015
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
S Kunte, J Abraham, AJ Montero
Cancer 126 (19), 4278-4288, 2020
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ...
American journal of clinical oncology 36 (2), 151-156, 2013
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in …
ML Salem, CM Díaz-Montero, AA Al-Khami, SA El-Naggar, O Naga, ...
The Journal of Immunology 182 (4), 2030-2040, 2009
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II …
AJ Montero, CM Diaz-Montero, YE Deutsch, J Hurley, LG Koniaris, ...
Breast cancer research and treatment 132, 215-223, 2012
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial
V Diaby, G Adunlin, AJ Montero
Pharmacoeconomics 32, 101-108, 2014
Cost-effectiveness of immune checkpoint inhibition in BRAF wild-type advanced melanoma
CG Kohn, SB Zeichner, Q Chen, AJ Montero, DA Goldstein, CR Flowers
Journal of Clinical Oncology 35 (11), 1194, 2017
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
AJ Montero, M Escobar, G Lopes, S Glück, C Vogel
Current oncology reports 14, 1-11, 2012
Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer
SB Zeichner, T Koru-Sengul, N Shah, Q Liu, NJ Markward, AJ Montero, ...
Clinical breast cancer 15 (1), e1-e11, 2015
Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer A phase 1 trial
AJ Ocean, KL Pennington, MJ Guarino, A Sheikh, T Bekaii‐Saab, ...
Cancer 118 (22), 5497-5506, 2012
Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin–agarose pulldown assay
WG Deng, Y Zhu, A Montero, KK Wu
Analytical biochemistry 323 (1), 12-18, 2003
The system can't perform the operation now. Try again later.
Articles 1–20